Symbols

CTIC(Delisted)

CTI BioPharma·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CTIC

Cti Biopharma Corp

A biopharmaceutical company that developing novel targeted therapies for blood-related cancers

Industry

Established Date

Listing Date

03/21/1997

Exchange

NASDAQ Stock Exchange

Full-time Employees

127

Fiscal Year Ends

12-31

Website

www.ctibiopharma.com

Security Type

Common stock

Office address

3101 Western Avenue, Suite 800, Seattle, WA

Business

Introduction

CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development and commercialization of methods to reduce toxicity and treat cancer more effectively. The company's goal is to generate revenue through the products it develops, and to build a profitable company alone or with one or more potential partners. At present, they are mainly focused on the treatment of blood-related cancers with huge medical needs. The first and foremost is to commercialize PIXUVRI in Europe. Provides a Phase 3 clinical trial for the treatment of highly relapsed, refractory, moderately and highly malignant non-Hodgkin's lymphoma and myelofibrosis. The company was founded in Washington in 1991.

Company Financials

EPS

CTIC has released its 2023 Q1 earnings. EPS was reported at -0.1, versus the expected -0.12, beating expectations. The chart below visualizes how CTIC has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CTIC has released its 2023 Q1 earnings report, with revenue of 24.12M, reflecting a YoY change of 950.81%, and net profit of -13.42M, showing a YoY change of 63.90%. The Sankey diagram below clearly presents CTIC's revenue sources and cost distribution.